Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02578771 · ClinicalTrials.gov registry record · Phase 3
Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle
A Phase 3 study, sponsored by Zurex Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 123
- Enrollment target
NCT02578771: Completed Phase 3 study, sponsored by Zurex Pharma.
NCT02578771 is a Phase 3 study that has completed, run by Zurex Pharma. The registered enrollment target is 123 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02578771, a Phase 3 study, has completed, sponsored by Zurex Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 123 participants
- Enrollment target
Study Summary
ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive control will be compared; ZuraPrep non-active and negative control will be compared. Each subject will receive two of the planned treatments, one on the left side of body and one of the right. Study duration for subjects - 3 to 4 weeks.
Primary Outcome
calculated as log-10 CFU responder rates from baseline
Interventions
- OTHER Normal Saline
- DRUG ZuraPrep with 70% IPA
- DRUG ZuraPrep without 70% IPA
- DRUG ChloraPrep CHG/IPA Teal Tint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 123 participants |
| Start Date | 2015-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
What the finished NCT02578771 record still lists
NCT02578771 is an interventional study that assigns participants to a tested intervention. The registered 123 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 4 interventions - of which Normal Saline is the first listed.
NCT02578771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02578771 about?
NCT02578771 is a clinical study titled "Pilot Clinical Evaluation to Characterize in Vivo Effects of Topically Applied ZuraPrep & ZuraPrep Vehicle". ZuraPrep is being evaluated for efficacy as a preoperative skin preparation solution to demonstrate its immediate and persistent antimicrobial properties. At least 72 subjects will be randomized utilizing bilateral applications on abdomen and groin. ZuraPrep active product and reference positive con...
What is the current status of trial NCT02578771?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 123 participants. The study started on 2015-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02578771?
The interventions under investigation include: Normal Saline (OTHER), ZuraPrep with 70% IPA (DRUG), ZuraPrep without 70% IPA (DRUG), ChloraPrep CHG/IPA Teal Tint (DRUG).
Who is sponsoring clinical trial NCT02578771?
This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02578771's enrollment target sits among peer trials
123 1615th of 2000 higher than 384 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05285891 · 123 participants · Phase 4
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
- NCT05334368 · 123 participants · Phase 3
Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial
- NCT06088355 · 123 participants · NA
Moderate Versus High Volume Light-Moderate Intensity Exercise for People With Moderate Parkinson's Disease
- NCT06111131 · 123 participants · NA
Ancora-SB Overtube Complete Positioning and Optical Visualization During Endoscopic Procedures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia